STOCK TITAN

Biomea Fusion to Participate in Jefferies Healthcare Conference

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Rhea-AI Summary

Biomea Fusion, a clinical-stage biopharmaceutical company (Nasdaq: BMEA), announced CEO Thomas Butler's participation in the Jefferies Healthcare Conference on June 8, 2022, at 2:30 PM ET. The event will feature a fireside chat where Butler will discuss the company's innovative approach to developing covalent small molecules aimed at treating genetically defined cancers and metabolic diseases. A live webcast of the chat will be available for 90 days post-event at Biomea Fusion Investors.

Loading...
Loading translation...
Argus Session date unavailable
+11.48% session move Open Argus
Details

News Market Reaction – BMEA

The recorded move for BMEA in the trading session of this news was +11.48%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

REDWOOD CITY, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced that Thomas Butler, Chief Executive Officer and Chairman of the Board, will participate in a fireside chat and meet with investors at the in-person Jefferies Healthcare Conference. The fireside chat will take place on Wednesday, June 8th at 2:30pm Eastern Time.

A live webcast of the fireside chat can be accessed at https://investors.biomeafusion.com/ and will be available for 90 days following the presentation.

About Biomea Fusion

Biomea Fusion is a biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response. The company is utilizing its proprietary FUSION™ System to advance a pipeline of covalent -binding therapeutic agents against key oncogenic drivers of cancer and metabolic diseases. Biomea Fusion’s goal is to utilize its capabilities and platform to become a leader in developing covalent small molecules in order to maximize the clinical benefit when treating various cancers and metabolic diseases.

Contact:

Van Sandwick
Director, Investor Relations & Corporate Development
vsandwick@biomeafusion.com
(650) 460-7759


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the date and time of the Biomea Fusion fireside chat at the Jefferies Healthcare Conference?

The fireside chat will take place on June 8, 2022, at 2:30 PM Eastern Time.

Who is participating in the Biomea Fusion fireside chat?

Thomas Butler, the CEO and Chairman of Biomea Fusion, will participate in the fireside chat.

Where can I watch the Biomea Fusion fireside chat?

You can access the live webcast at Biomea Fusion Investors.

How long will the Biomea Fusion webcast be available after the fireside chat?

The webcast will be available for 90 days following the presentation.

What is the focus area of Biomea Fusion?

Biomea Fusion specializes in discovering and developing covalent small molecules for treating genetically defined cancers and metabolic diseases.

Keep reading